Published in 2017 – Ann Oncol (2017) 28 (suppl 4): iv41–iv51
Authors: A. Hochhaus, S. Saussele, G. Rosti, F.-X. Mahon, J. J. W. M. Janssen, H. Hjorth-Hansen, J. Richter and C. Buske
The prevalence of chronic myeloid leukaemia is steadily rising due to the substantial prolongation of survival that has been achieved with targeted therapy. These updated guidelines on chronic myeloid leukaemia provide updated treatment recommendations including the monitoring and management of side effects, as well as a new treatment algorithm for chronic phase chronic myeloid leukaemia patients.